LRP及β-Tubulin在非小细胞肺癌组织中表达及其与肿瘤耐药的关系  

Expression and Correlation of LRP and β-Tubulin in Non-small Cell Lung Cancer and its Relationship with Tumor Multidrug Resistance

作　　者：董西林[1] 周晶[1] 陈真真[1] 王雅娟[1] 李家芝[1] 

机构地区：[1]西安交通大学医学院第二附属医院呼吸内科

出　　处：《实用癌症杂志》2010年第5期460-463,466,共5页The Practical Journal of Cancer

基　　金：陕西省卫生厅科研基金(NO06D38)

摘　　要：目的探讨肺耐药蛋白(LRP)及β-微管蛋白(β-Tubulin)与肿瘤多药耐药的关系,为非小细胞肺癌(NSCLC)患者化疗方案的选择和改进提供理论依据。方法应用免疫组织化学技术(SP法),检测NSCLC组织中LRP及β-Tubulin表达情况。结果 LRP在NSCLC中阳性表达率为73.33%,其中鳞癌表达率(54.55%)低于腺癌(76.92%),但两者之间无显著性差异;LRP表达与肺癌分化程度有明显关系(P<0.05),高、中、低分化表达率分别为53.85%、66.67%、91.30%;分化程度越低,LRP表达越强;βⅢ-tubulin在NSCLC中阳性表达率为76.67%。LRP及βⅢ-tubulin阳性表达与患者性别、是否吸烟、病理类型、临床分期均无明显关系;LRP与βⅢ-tubulin表达间呈明显正相关关系(γ=0.293,P<0.05)。结论 LRP及βⅢ-Tubulin在NSCLC组织中呈高表达,LRP表达与肺癌分化程度有关。LRP及βⅢ-Tubulin表达与患者性别、是否吸烟、病理类型、临床分期均无明显关系;LRP与βⅢ-tubulin表达呈正相关,耐药相关蛋白表达规律可能有助于NSCLC化疗方案的选择,为临床化疗方案的制定及多药耐药机制的研究提供理论依据。Objective To detect the expression of LRP and βⅢ-tubulin,and analyze its clinical relationship for patients with NSCLC.Methods The expression of LRP and βⅢ-tubulin in NSCLC was detected by immunohistochemical method.Results Positive expression rate of LRP in NSCLC was 73.33%.The expression rate of LRP in squamous cell carcinoma (54.55%) was lower than that in adenocarcinoma (76.92%),but they showed no significant difference by the statistical test.Expression of LRP significantly correlated with the degree of differentiation(P<0.05),and the expression rate in well,moderately and poorly differentiated was 53.85%,66.67% and 91.30,respectively.Positive expression rate of βⅢ-tubulin in NSCLC was 76.67%.The expression of βⅢ-tubulin was not correlated with histological types,sex,smoking status,and clinical stages.The expression of LRP and βⅢ-tubulin(γ=0.293,P<0.05)was positively correlated.Conclusion LRP and βⅢ-tubulin are highly expressed in NSCLC.The expression of LRP is correlated with the degree of cell differentiation in NSCLC,and the expression of LRP and βⅢ-tubulin is positively correlated.

关 键 词：非小细胞肺癌 多药耐药 肺耐药蛋白 Β-微管蛋白 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]